Progenier

Progenra is a biotechnology company focused on the discovery and development of novel therapeutics that target the ubiquitin-proteasome pathway (UPP). Utilizing its proprietary Ubi-Pro platform, the company identifies small molecule modulators of deubiquitylating enzymes (DUBs) and E3 ligases to treat cancer, inflammation, and neurodegenerative disorders. Progenra's approach includes both inhibitors of DUBs to promote protein degradation and activators to stabilize beneficial proteins. The company has established significant research collaborations with major pharmaceutical partners to advance its pipeline of first-in-class drug candidates. Progenra is positioned as a leader in the emerging field of protein homeostasis and targeted protein degradation.